Close this search box.

Deals Report: Syncona merging Freeline, SwanBio to form Spur


Plus: AbbVie licenses TL1A mAb from FutureGen for IBD, and updates from Takeda, Ascentage, Pfizer, ProFound and more

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst

June 18, 2024 12:28 AM UTC

Months after taking Freeline Therapeutics Ltd. private with a narrowed focus on a gene therapy for Gaucher disease, Syncona Ltd. (LSE:SYNC) is merging it with another portfolio company, SwanBio Therapeutics Inc., rebranding the combined entity as Spur Therapeutics Ltd., and supplying $50 million to advance a pair of clinical programs.

The arrangement is structured as an acquisition of SwanBio by Freeline. The deal adds SwanBio’s SBT-101, a gene therapy for adrenomyeloneuropathy that is in Phase I/II testing, to a pipeline that is led by gene therapy FLT201 for Gaucher disease. Spur is lining up a Phase III study of the Gaucher program to begin next year…